Cancer Center to be the First in Europe to Install a CyberKnife VSI System, the Latest Generation of the CyberKnife System

The Leon-Berard Center of Lyon, France, is now offering its cancer patients the benefits of Full Body Radiosurgery

SUNNYVALE, California, September 1, 2010 - Accuray Incorporated (Nasdaq: ARAY), a global leader in the field of
radiosurgery, today announced that the first CyberKnife VSI System to be
installed in Europe was placed at the Leon-Berard Cancer Multidisciplinary
Center (CLB) in Lyon, France. The CyberKnife VSI System is the newest
addition to the CyberKnife product family.

One of France's leading cancer treatment facilities, the Leon-Berard
Cancer Center, is a non-profit hospital dedicated to cancer treatment and
research located in the Rhone-Alpes, the second largest region in France .
The addition of the CyberKnife System to the already well-equipped Radiation
Oncology department, - which features five treatment accelerators, one
dedicated scanner and one brachytherapy suite, - will expand the range of
therapeutic options available to the center's 2,000 yearly cancer patients.

"We feel strongly that the CyberKnife VSI System will help us deliver not
only more typical radiation therapy, but also allow us to treat cancer
patients that would otherwise have no other options," said Christian Carrie,
M.D., head of the Radiation Oncology department at CLB. "Although the
CyberKnife VSI System has the capacity to deliver conventional fractionation,
the main reason we chose this system is for its superior accuracy and
efficiency in the treatment of moving targets, in particularly liver and
prostate."

With the CyberKnife VSI System, clinicians at Leon-Berard will now be
able to broaden delivery of high precision radiation therapy and radiosurgery
for extracranial indications. This new expertise will increase the range of
radiation treatments available at the Leon-Berard Cancer Center, which
already include respiratory gating radiation therapy, extracranial
stereotactic radiation therapy, interstitial brachytherapy, intensity
modulated conformal radiotherapy (IMRT), and total body irradiation (TBI).

"We are very proud to work with such a prestigious and highly scientific
cancer center and announce that patients will soon have access to CyberKnife
VSI treatments," said Guillaume Tetard, Senior Director of Sales, Accuray
EIMEA (Europe India Middle East and Africa). "Given the increase in cancer
diagnosis in France, now more than ever it is crucial that patients have
access to the latest technologies in oncology care. We are confident that as
acceptance of the CyberKnife System grows, it will improve cancer care
throughout Europe by bringing more therapeutic options to doctors and
patients."

The CyberKnife System uses real-time tracking and correction capabilities
to deliver high-dose radiation to tumors with pin-point accuracy, including
tumors that move with respiration or unpredictably due to other normal bodily
functions. As a non-invasive treatment for cancerous and non-cancerous
lesions, the CyberKnife System does not rely on sub-optimal techniques such
as gating to account for movement, nor does the system require the use of
stabilizing head and body frames that are extremely uncomfortable for
patients. The target tracking technologies of the CyberKnife System make it
an easy and comfortable experience for the patient, while providing industry
leading radiation delivery accuracy. Treatments are usually completed in one
to five sessions with each session typically lasting between 20-45 minutes.
In most cases, patients can resume their normal activities immediately
following treatment.

About Leon-Berard Cancer Center

The Leon-Berard Cancer Center is a private, non-profit hospital dedicated
to cancer treatment and research. As a leader in its field and a pole of
reference for the treatment of cancer in the Rhone-Alpes region (which
includes 8 sub-regions: Ain, Ardeche, Drome, Isere, Loire, Rhone, Savoie,
Haute-Savoie), the center is affiliated with the French Federation of Cancer
Centers. It also exerts strong influence outside the region, with many
patients coming from other regions of France as well as foreign countries to
get treated there. It is also important to note that this center has received
full, unreserved agreement of the HAS (Haute Autorite de Sante, a French
governmental organization aimed at evaluating the quality of services
delivered in healthcare facilities around the country).

About the CyberKnife(R) Robotic Radiosurgery System

The CyberKnife Robotic Radiosurgery System is the world's only robotic
radiosurgery system designed to treat tumors anywhere in the body
non-invasively. Using continual image guidance technology and computer
controlled robotic mobility, the CyberKnife System automatically tracks,
detects and corrects for tumor and patient movement in real-time throughout
the treatment. This enables the CyberKnife System to deliver high-dose
radiation with pinpoint precision, which minimizes damage to surrounding
healthy tissue and eliminates the need for invasive head or body
stabilization frames.

About Accuray

Accuray Incorporated (Nasdaq: ARAY), based in Sunnyvale, Calif., is a
global leader in the field of radiosurgery dedicated to providing an improved
quality of life and a non-surgical treatment option for those diagnosed with
cancer. Accuray develops and markets the CyberKnife Robotic Radiosurgery
System, which extends the benefits of radiosurgery to include extracranial
tumors, including those in the spine, lung, prostate, liver and pancreas. To
date, the CyberKnife System has been used to treat more than 95,000 patients
worldwide and currently more than 206 systems have been installed in leading
hospitals in the Americas, Europe and Asia. For more information, please
visit www.accuray.com.

Safe Harbor Statement

The foregoing may contain certain forward-looking statements that involve
risks and uncertainties, including uncertainties associated with the medical
device industry. Except for the historical information contained herein, the
matters set forth in this press release, including statements relating to
clinical acceptance, clinical benefits, clinical publications, and clinical
results are forward-looking statements within the meaning of the "safe
harbor" provisions of the Private Securities Litigation Reform Act of 1995.
Forward-looking statements speak only as of the date the statements are made
and are based on information available at the time those statements are made
and/or management's good faith belief as of that time with respect to future
events. You should not put undue reliance on any forward-looking statements.
Important factors that could cause actual performance and results to differ
materially from the forward-looking statements we make include: market
acceptance of products; competing products, the combination of our products
with complementary technology; and other risks detailed from time to time
under the heading "Risk Factors" in our report on Form 10-K for the 2010
fiscal year which has been filed with the Securities and Exchange
Commission.. The Company's actual results of operations may differ
significantly from those contemplated by such forward-looking statements as a
result of these and other factors. We assume no obligation to update
forward-looking statements to reflect actual performance or results, changes
in assumptions or changes in other factors affecting forward-looking
information, except to the extent required by applicable securities laws.

Stephanie Tomei of Accuray Incorporated, +1-408-789-4234, stomei at accuray.com; or Sancie Nakarat, Manager, EU Marketing, +33-(0)-6-81-36-84-34, snakarat at accuray.com; or Fleur de Lempdes, Edelman Paris, +33-(0)-1-56-69-75-23, fleur.delempdes at edelman.com, both for Accuray Incorporated